Rituximab Treatment of Focal Segmental Glomerulosclerosis
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the approved drug, rituximab, is effective
in the treatment of focal segmental glomerulosclerosis (FSGS)
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)